Compulsory licensing in Canada—revisited

On March 25, 2020, the government of Canada acted swiftly to enact legislation in response to COVID-19. The legislation, which was introduced into Parliament just the day before, brought sweeping changes to various aspects of Canadian law, including expanding the compulsory licensing framework in the Patent Act.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

Bausch reaches deal with competitor over IBS drug generic

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

mRNA litigation: Who’s winning, who’s filing, and what’s next

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

Compulsory licensing in Canada—revisited

More on this story

Editor's picks

Editor's picks

More features